


1



2



3

OBJECTIVES 2026 MEDICALLY INTEGRATED PHARMACY SPRING FORUM

1. Discuss how medically integrated pharmacy workflows support coordination, monitoring, and continuity for oral and combination oncology regimens.
2. Review the different distribution channels for oncology drugs, and how each one potentially affects patient care.
3. Describe common operational barriers that limit a practice's ability to implement Oncology Optimized Limited Distribution (OOLD) therapies
4. Review practical strategies for routing, escalation, and payer override workflows to protect timely access to OOLD medications

2026 MEDICALLY INTEGRATED PHARMACY SPRING FORUM

4

NCODA
Professional Development Education Series

Understanding the role of Medically Integrated Pharmacy (MIP) and its clinical and operational teams, along with how the differing drug distribution channels affect patient care.

NCODA

Medically Integrated. Patient-Centered.

5

Medically Integrated Pharmacy (MIP) NCODA

- A Medically Integrated Dispensing Pharmacy (MIP) is a pharmacy embedded within a cancer center, enabling oncology care teams to work collaboratively in one setting.
- This model enhances patient care through coordinated services, personalized support, and improved communication across the care team.
- By integrating pharmacy services on-site, patients experience more efficient, seamless, and effective treatment.

Reed LE, Gregg ST, Doshi GC, et al. Medically integrated dispensing pharmacy: AGO/Network for Collaborative Oncology Development & Advancement standards update. JCO Oncol Pract. 2025;21(15):1581-1591. DOI:10.1200/JCO.2024.21.1581. PMID: 40888888. URL: https://doi.org/10.1200/JCO.2024.21.1581. Press. 2025. Medically Integrated Pharmacy (MIP) Professional Development Education Series. https://www.ncoda.org/education/professional-development/medically-integrated-pharmacy. Accessed April 2026.

6



Distribution Models

Closed Distribution: Applies to medications with highly restricted networks, such as those requiring REMS (Risk Evaluation & Mitigation Strategies) or manufacturer designated controls. These models typically offer little to no flexibility in dispensing, often excluding MIPs altogether. This includes models with no MIP Access.

Open Distribution: Medications widely available through retail, hospital and PBM (Pharmacy Benefit Manager) affiliated and non-affiliated mail order pharmacies without restrictions.

PBM Influenced Limited Distribution: Includes one or two PBM affiliated mail order pharmacies. While not preferred, it is important to recognize manufacturers that are attempting to promote MIPs and limit access to PBM-owned pharmacies.

Oncology Optimized Limited Distribution (OOLD): Represents the NCODA preferred model, where PBM affiliated mail order pharmacies are excluded, and MIPs and non-PBM affiliated pharmacies can dispense. This model enables coordinated, in-practice care and supports timely, patient-centered treatment.

Academy of Managed Care Pharmacy (AMCP), AMCP Guide to Pharmaceutical Payment Methods, 4th ed., Alexandria, VA, AMCP, 2013
Mullaly AP, White JP, East SR. The Cost of Specialty Drugs in the United States. Santa Monica, CA: RAND Corporation; 2019.


Medically Integrated. Patient-Centered.

7

OOLD Impact in Access, Coordination and Outcomes

The OOLD model enables coordinated, in-practice care and supports timely, patient-centered treatment and is critical for achieving optimal clinical outcomes:


- Delivers enhanced oncology care directly to patients through coordinated, in-practice services
- Improves patient satisfaction with streamlined, well-aligned support and fewer unnecessary clinic visits
- Enables proactive monitoring and management of adverse effects, helping reduce hospitalizations
- Increases adherence and compliance through consistent oversight
- Minimizes medication waste with more efficient and optimized dispensing practices
- Boosts practice capture rates, driving greater revenue and operational efficiency




Medically Integrated. Patient-Centered.

8

IntrinsiQ Data on Limited Distribution Drug Capture Rates



	Network 1	Network 2	Network 3
Network Description	Open	PBM Influenced	OOLD
% Internal Capture	60.43%	81.94%	89.08%
All Payors	58%	79%	98%
Commercial Payors	15%	40%	95%




IntrinsiQ Specialty Solutions. Measuring prescriber capture rates of medically integrated dispensing sites. An AMCP/AMCP Specialty Network member presentation. Published May 2025. Accessed April 4, 2025.

Medically Integrated. Patient-Centered.

9

Barriers to OOLD Utilization

Practice Barriers vs PBM Barriers



10

Open / PBM-Restricted Impact

Practice
Reduced ability to monitor/ manage:

- Adherence/compliance
- Adverse Drug Events (ADEs)
- Interactions/ contraindications


Potential delays in therapy:

- Prior Auth/Financial Assistance
- Communication with outside specialty pharmacies (SPs)
- Turnaround time

Reduction in revenue

→

- Reduced level of patient care
- Delays to starting/continuing treatment
- Potential increased cost (i.e. hospitalization, ADE management)
- Decreased patient satisfaction



11


Protecting Access



12

Strategies to Protect Access to OOLD

- **Work with your Pharma Partners:**
 - Talk to your pharma partners when they visit your practice site.
 - Explain and educate to the partners how important OOLD is to your patients and your practice, especially when reviewing pipeline products.
- **Utilize OOLD medications whenever possible:**
 - Safety and efficacy aside, maximizing OOLD dispensing increases capture rate, which improves patient care, increases practice revenue, and sends a message to pharma partners.
- **Fight for that script!**
 - If you are an MIP and the drug is OOLD, try and fill that prescription.
 - Call the PBM to attempt an override.



Medically Integrated. Patient-Centered.

13

Tools to Assist:

OOLD Tool:
 NCODA hosts a free resource on its site to determine the distribution channel of drugs by drug or disease state:

At Disease:

Generic	Class	Manufacturer	Distribution Channel by NCODA	Pharmacy
Alectinib	MSDL (ALK)	Genentech	Open	Open Distribution
Bupropion	MSDL (ALK)	Takeda	Oncology Optimized Limited Distribution	MRP (Boehringer, OncORP)
Lorazepam	MSDL (ALK)	Pfizer	Open	Open Distribution
Oprelvekin	MSDL (ALK)	Pfizer	Open	Open Distribution
Carbimab	MSDL (ALK)	Novartis	Open	Open Distribution

1 of 1 pages (2 items)

Mfr. Websites/Field Reps/Access Teams




NCODA. Oncology Optimized Limited Distribution Table. <https://ncoda.org/oold-table/>. Accessed April 2026

Medically Integrated. Patient-Centered.

14

Practice Tools


- Embed OOLD therapy options in Electronic Medical Record (EMR)
- Notation in Pharmacy software
- Assign pharmacy staff to proactively review, monitor and intervene




Medically Integrated. Patient-Centered.

15


Summary




Medically Integrated Practices (MIPs) are uniquely positioned to deliver comprehensive, high-quality oncology care through close clinical coordination and direct patient management.



Oncology Optimized Limited Distribution Drugs (LDDs) enable coordinated, in-practice care, ensuring timely access to treatment and a more patient-centered experience.



Work with your partners and within your practice to drive OOLD utilization. Educate, use tools and continue to drive the message of enhanced patient care.




Medically Integrated. Patient-Centered.

16

QUESTION & ANSWER | 2025 MEDICALLY INTEGRATED ONCOLOGY SPRING FORUM

Protecting Access to Oncology-Optimized Limited Distribution Drugs


Kyle Kitchen, PharmD, MBA
Ken Komorny, PharmD
Douglas Braun, PharmD, CSP, CPh
Jonas Congelli, RPh




17

CE CODE | 2025 MEDICALLY INTEGRATED ONCOLOGY SPRING FORUM

Protecting Access to Oncology-Optimized Limited Distribution Drugs



18



19